semaglutide cardiovascular outcomes news 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Oral Semaglutide and Cardiovascular Outcomes

Peng D, Hu T, Soutto M, Belkhiri A, Zaika A, El-Rifai W

This indicates an interesting GSH-dependent threshold regulation that is important for the subset-specific functions of B cells and a differential redox-dependent regulation of metabolic activities in these cells

Liposomal Glutathione (Gold Standard for Absorption) Liposomal glutathione is designed to protect the fragile glutathione molecule by encasing it within phospholipid layers similar to cell membranes

Clothes fit better

Cardiovascular applications

GLP-1 use is highest among people ages 50-64: 30% in this age group have ever taken them and 22% are currently using them